MORI-BUILDING
18.2.2021 06:02:05 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that it will partner with Aman, the operator of diverse world-class luxury hotels and resorts, in the Toranomon-Azabudai Urban Redevelopment Project, a massive urban renewal undertaking that will revitalize a large area of central Tokyo when completed in 2023. The two main outcomes of the partnership will be the branded residence Aman Residences, Tokyo and luxury hotel Janu Tokyo , Aman’s sister brand, marking the debut of the Janu brand in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217006076/en/
Shingo Tsuji, President and CEO of Mori Building, said: “Tokyo must add to its magnetic power if it is to succeed in its competition with the world’s greatest cities. Mori Building is joining hands with Aman, which operates diverse world-class resorts, to provide a world-leading residential environment and hotel unlike anything ever seen in Tokyo, where people will achieve harmony with nature as well as connect with and inspire others through creativity. By realizing this new form of ‘urban wellness,’ Mori Building will enhance Tokyo's magnetic power.”
Vladislav Doronin, Chairman and CEO of Aman and Janu, said: “Launching our first urban Aman Residences in Japan is a milestone moment in the history of Aman and speaks to our brand’s close relationship and symbiosis with this country and its incredibly special culture. Working with leading developers Mori Building, and being part of the Toranomon-Azabudai project, will enable us to bring to life Aman’s fifth development within Japan, this time offering a permanent sanctuary for owners as well as exclusive access to the Aman lifestyle. Furthermore, it will provide the setting for Janu Tokyo. In this hub of culture and art, we want to connect guests to the heart of this vibrant community and offer a chance for creative expression.”
Aman Residences, Tokyo — incomparable urban residential experiences
Aman Residences, Tokyo will be located on floors 54–64 of the 330-meter A District Tower, will offer 91 hotel-branded residences with exclusive services, including a residents-only Aman Spa (some 1,400 m²). Aman’s signature hospitality—both warm and unassuming—will enable residents to enjoy extraordinarily peaceful lifestyles while overlooking the vibrant Tokyo metropolis. The Tower’s sophisticated architectural design is the masterful work of Pelli Clarke Pelli Architects (USA) and interior design has been crafted by Yabu Pushelberg (Canada).
Janu Tokyo — Aman’s sister brand debuts in Japan
Aman’s luxury hotel brand Janu will make its Japan debut with Janu Tokyo on floors 1–13 in the B-2 District Tower. The hotel is designed by Denniston (Malaysia) under the leadership of Jean-Michel Gathy. In addition to approx. 120 luxury rooms, all offering excellent views of a central square filled with lush greenery, Janu Tokyo will boast Japan’s largest spa (some 3,500 m²) with spa treatment and a fitness center, six restaurants, and a cafe and bars for leisure and business gatherings. Janu Tokyo will welcome guests from around the world.
About Aman
Aman was founded in 1988 with the vision of building a collection of intimate retreats with the unassuming, warm hospitality of a gracious private home. The first, Amanpuri (place of peace) in Phuket, Thailand, introduced the concept and, since then, Aman has grown to encompass 33 exquisitely serene hotels and resorts in 20 destinations across the world, with a further seven under construction. The next Aman to open will be Aman New York. In 2020, a new hotel brand, Janu - meaning ‘soul’ in Sanskrit was unveiled. Janu offers a unique take on hospitality where genuine human interaction, playful expression and social wellness are at the core of the experience. Janu aims to bring balance to the head and heart and rekindle the soul. Janu launches with three forthcoming hotels which are already under construction: Montenegro (2022), Al Ula in Saudi Arabia (2022) and Tokyo (2023), as well as a robust pipeline of future hotels.
About Mori Building
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en
Related Links
Press release “Mori Building Unveils Massive Urban Regeneration Project In Central Tokyo” published on August 22, 2019:
https://www.mori.co.jp/en/img/article/190822.pdf
Toranomon-Azabudai Project Fact Book:
https://www.mori.co.jp/en/projects/toranomon_azabudai/img/fact_book.pdf
Toranomon-Azabudai Project Image Movie:
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217006076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom